Stock Analysis

Clever Culture Systems First Half 2025 Earnings: EPS: AU$0.001 (vs AU$0.003 loss in 1H 2024)

ASX:CC5
Source: Shutterstock

Clever Culture Systems (ASX:CC5) First Half 2025 Results

Key Financial Results

  • Revenue: AU$2.82m (up 297% from 1H 2024).
  • Net income: AU$1.11m (up from AU$1.83m loss in 1H 2024).
  • Profit margin: 39% (up from net loss in 1H 2024). The move to profitability was primarily driven by higher revenue.
  • EPS: AU$0.001 (up from AU$0.003 loss in 1H 2024).
earnings-and-revenue-history
ASX:CC5 Earnings and Revenue History February 25th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Clever Culture Systems' share price is broadly unchanged from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 6 warning signs for Clever Culture Systems (3 can't be ignored) you should be aware of.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About ASX:CC5

Clever Culture Systems

Engages in the research, development, and commercialization of technology solutions for medical industry in Australia, the United States, Sweden, the United Kingdom, and Germany.

Medium-low with mediocre balance sheet.